Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

<< Previous

Bullboard Posts

Next >>

(54)
•••

Post by willyk3on Mar 20, 2021 12:49pm

161 Views

Post# 32845115

Times a wasting

No news at all. Wonder whats up with that resubmission?
Shouldnt financials be out for this quarter?
I thought they were reasonably cashed up but lack of any communication from the company is disconcerting

<< Previous

Bullboard Posts

Next >>

Copper Lake opens $2.5M financing round for Marshall Lake